YC S20
Nephrogen
Curative genetic medicines for kidney diseases
About
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Nephrogen.
See family office activityIndustry & Focus
HealthcareTherapeuticsGene TherapyCRISPRBiotech